TABLE OF CONTENTS
1 INTRODUCTION 42
1.1 OBJECTIVES OF THE STUDY 42
1.2 MARKET DEFINITION 42
1.3 OVERVIEW OF THE ASIA PACIFIC CONTRACT MANUFACTURING MARKET 42
1.4 CURRENCY AND PRICING 44
1.5 LIMITATIONS 44
1.6 MARKETS COVERED 44
2 MARKET SEGMENTATION 47
2.1 MARKETS COVERED 47
2.2 GEOGRAPHICAL SCOPE 48
2.3 YEARS CONSIDERED FOR THE STUDY 49
2.4 DBMR TRIPOD DATA VALIDATION MODEL 50
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 53
2.6 MULTIVARIATE MODELLING 54
2.7 PRODUCT SEGMENT LIFELINE CURVE 54
2.8 MARKET END USER COVERAGE GRID 55
2.9 DBMR MARKET POSITION GRID 56
2.10 VENDOR SHARE ANALYSIS 57
2.11 SECONDARY SOURCES 58
2.12 ASSUMPTIONS 58
3 EXECUTIVE SUMMARY 59
4 PREMIUM INSIGHTS 61
4.1 PESTEL ANALYSIS 62
4.2 PORTER'S FIVE FORCES 63
4.3 STRATEGIC INITIATIVES: 64
5 REGULATORY FRAMEWORK 65
5.1 REGULATORY SCENARIO BY FDA 65
5.2 REGULATORY SCENARIO IN AUSTRALIA 66
5.3 REGULATORY SCENARIO IN EUROPE FOR MEDICINES 67
6 MARKET OVERVIEW 68
6.1 DRIVERS 70
6.1.1 COST-EFFECTIVENESS FOR THE MANUFACTURING COMPANIES 70
6.1.2 RISE OF TECHNOLOGICAL ADVANCEMENTS IN CONTRACT MANUFACTURING 70
6.1.3 ASIA PACIFIC PRESENCE AND CONNECTED NETWORK 71
6.2 RESTRAINTS 71
6.2.1 STRINGENT REGULATIONS AMONG VARIOUS JURISDICTIONS 71
6.2.2 RISK OF CONFIDENTIAL INFORMATION 72
6.3 OPPORTUNITIES 72
6.3.1 PATENT EXPIRY AND INCREASING DEMAND FOR GENERIC DRUGS 72
6.3.2 GROWING EXPENSES ON THE DEVELOPMENT OF HEALTHCARE INFRASTRUCTURE 73
6.3.3 INCREASE IN NUMBER OF STRATEGIC INITIATIVES BY KEY MARKET PLAYERS 73
6.4 CHALLENGES 74
6.4.1 INTELLECTUAL PROPERTY RISKS 74
6.4.2 INCREASE IN NUMBER OF PHARMACEUTICAL COMPANIES TO SET UP THEIR MANUFACTURING SITES 74
7 ASIA PACIFIC CONTRACT MANUFACTURING MARKET, BY PRODUCT 75
7.1 OVERVIEW 76
7.2 PHARMACEUTICAL PRODUCTS MANUFACTURING 79
7.2.1 TYPES OF PRODUCTS 80
7.2.1.1 TABLETS 80
7.2.1.2 CAPSULES 80
7.2.1.3 BIOLOGICS 81
7.2.1.4 SMALL MOLECULE 81
7.2.1.5 CELL & GENES MANUFACTURING 81
7.2.1.6 NUTRACEUTICALS 81
7.2.1.7 OTHERS 81
7.2.2 TYPE OF SERVICES 81
7.2.2.1 DRUG DEVELOPMENT SERVICES 82
7.2.2.2 TABLET MANUFACTURING SERVICES 82
7.2.2.3 BIOLOGICS API MANUFACTURING 82
7.2.2.4 BIOLOGICS FDF MANUFACTURING SERVICES 82
7.2.2.5 OTHERS 82
7.2.3 BY DOSAGE FORM 82
7.2.3.1 SOLID FORMULATIONS 83
7.2.3.2 LIQUID FORMULATIONS 83
7.2.3.2.1 INJECTABLE 83
7.2.3.2.2 SYRUPS 83
7.2.3.3 SEMI-SOLID FORMULATIONS 83
7.2.3.4 TOPICAL DRUG FORMULATIONS 83
7.2.3.5 OTHERS 83
7.3 MEDICAL DEVICE MANUFACTURING 84
7.3.1 TYPE OF DEVICES 85
7.3.1.1 SYRINGES AND NEEDLES 86
7.3.1.2 INFUSION DEVICES & ADMINISTRATION SETS 86
7.3.1.3 MEDICAL ACCESSORIES, COMPONENTS & CONSUMABLES 86
7.3.1.4 DISPOSABLES 86
7.3.1.5 IVD DEVICES 87
7.3.1.6 CARDIOVASCULAR DEVICES 87
7.3.1.7 DIABETES CARE DEVICES 87
7.3.1.8 GENERAL SURGERY DEVICES 87
7.3.1.9 ORTHOPEDIC DEVICES 87
7.3.1.10 RESPIRATORY DEVICES 87
7.3.1.11 OPHTHALMIC DEVICES 87
7.3.1.12 DENTAL DEVICES 87
7.3.1.13 GYNECOLOGY/UROLOGY DEVICES 87
7.3.1.14 LABORATORY EQUIPMENT 87
7.3.2 TYPE OF SERVICES 88
7.3.2.1 MEDICAL DEVICE DESIGN AND DEVELOPMENT 88
7.3.2.2 DEVICE ASSEMBLY 88
7.3.2.3 REGULATORY ASSISTANCE 88
7.3.2.4 PACKAGING & LABELLING 88
7.3.2.5 STERILIZATION SERVICES 89
7.3.2.6 TRAINING AND VALIDATION 89
7.3.2.7 QUALITY ASSURANCE 89
7.3.2.8 OTHERS 89
7.3.3 BY DEVICE CLASS 89
7.3.3.1 CLASS I MEDICAL DEVICES 90
7.3.3.2 CLASS IIA MEDICAL DEVICES 90
7.3.3.3 CLASS IIB MEDICAL DEVICES 90
7.3.3.4 CLASS III MEDICAL DEVICES 90
8 ASIA PACIFIC CONTRACT MANUFACTURING MARKET, BY END USER 91
8.1 OVERVIEW 92
8.2 PHARMACEUTICAL COMPANIES 95
8.3 BIOTECHNOLOGY COMPANIES 95
8.4 BIOPHARMA COMPANIES 96
8.5 MEDICAL DEVICES COMPANIES 97
8.6 ORIGINAL EQUIPMENT MANUFACTURER 97
8.7 RESEARCH INSTITUTES 98
9 ASIA PACIFIC CONTRACT MANUFACTURING MARKET, BY DISTRIBUTION CHANNEL 99
9.1 OVERVIEW 100
9.2 RETAIL SALES 103
9.3 DIRECT TENDER 104
9.4 OTHERS 105
10 ASIA PACIFIC CONTRACT MANUFACTURING MARKET, BY REGION 106
10.1 ASIA PACIFIC 107
10.1.1 JAPAN 120
10.1.2 CHINA 128
10.1.3 SOUTH KOREA 136
10.1.4 INDIA 143
10.1.5 AUSTRALIA 151
10.1.6 SINGAPORE 159
10.1.7 THAILAND 167
10.1.8 MALAYSIA 175
10.1.9 INDONESIA 183
10.1.10 PHILIPPINES 191
10.1.11 REST OF ASIA-PACIFIC 199
11 ASIA PACIFIC CONTRACT MANUFACTURING MARKET: COMPANY LANDSCAPE 200
11.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 200
12 SWOT ANALYSIS 201
13 COMPANY PROFILE 202
13.1 AENOVA GROUP 202
13.1.1 COMPANY SNAPSHOT 202
13.1.2 COMPANY SHARE ANALYSIS 202
13.1.3 PRODUCT PORTFOLIO 203
13.1.4 RECENT DEVELOPMENTS 203
13.2 THERMO FISHER SCIENTIFIC INC. 204
13.2.1 COMPANY SNAPSHOT 204
13.2.2 REVENUE ANALYSIS 205
13.2.3 COMPANY SHARE ANALYSIS 205
13.2.4 PRODUCT PORTFOLIO 206
13.2.5 RECENT DEVELOPMENTS 206
13.3 EVONIK INDUSTRIES AG 207
13.3.1 COMPANY SNAPSHOT 207
13.3.2 REVENUE ANALYSIS 207
13.3.3 COMPANY SHARE ANALYSIS 208
13.3.4 PRODUCT PORTFOLIO 208
13.3.5 RECENT DEVELOPMENTS 208
13.4 LONZA 209
13.4.1 COMPANY SNAPSHOT 209
13.4.2 REVENUE ANALYSIS 209
13.4.3 COMPANY SHARE ANALYSIS 210
13.4.4 PRODUCT PORTFOLIO 210
13.4.5 RECENT DEVELOPMENTS 211
13.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH. 212
13.5.1 COMPANY SNAPSHOT 212
13.5.2 REVENUE ANALYSIS 212
13.5.3 COMPANY SHARE ANALYSIS 213
13.5.4 PRODUCT PORTFOLIO 213
13.5.5 RECENT DEVELOPMENTS 213
13.6 ABBVIE INC. 214
13.6.1 COMPANY SNAPSHOT 214
13.6.2 REVENUE ANALYSIS 214
13.6.3 PRODUCT PORTFOLIO 215
13.6.4 RECENT DEVELOPMENT 215
13.7 ALMAC GROUP 216
13.7.1 COMPANY SNAPSHOT 216
13.7.2 PRODUCT PORTFOLIO 216
13.7.3 RECENT DEVELOPMENTS 216
13.8 AVID BIOSERVICES, INC. 217
13.8.1 COMPANY SNAPSHOT 217
13.8.2 REVENUE ANALYSIS 217
13.8.3 PRODUCT PORTFOLIO 218
13.8.4 RECENT DEVELOPMENT 218
13.9 BAXTER 219
13.9.1 COMPANY SNAPSHOT 219
13.9.2 REVENUE ANALYSIS 219
13.9.3 PRODUCT PORTFOLIO 220
13.9.4 RECENT DEVELOPMENTS 221
13.10 CATALENT, INC 222
13.10.1 COMPANY SNAPSHOT 222
13.10.2 REVENUE ANALYSIS 222
13.10.3 PRODUCT PORTFOLIO 223
13.10.4 RECENT DEVELOPMENT 223
13.11 FAMAR HEALTH CARE SERVICES 224
13.11.1 COMPANY SNAPSHOT 224
13.11.2 PRODUCT PORTFOLIO 224
13.11.3 RECENT DEVELOPMENTS 224
13.12 JUBILANT PHARMA LIMITED 225
13.12.1 COMPANY SNAPSHOT 225
13.12.2 REVENUE ANALYSIS 225
13.12.3 PRODUCT PORTFOLIO 226
13.12.4 RECENT DEVELOPMENT 226
13.13 KIMBALL INTERNATIONAL 227
13.13.1 COMPANY SNAPSHOT 227
13.13.2 REVENUE ANALYSIS 227
13.13.3 PRODUCT PORTFOLIO 228
13.13.4 RECENT DEVELOPMENT 228
13.14 MERCK KGAA 229
13.14.1 COMPANY SNAPSHOT 229
13.14.2 REVENUE ANALYSIS 229
13.14.3 PRODUCT PORTFOLIO 230
13.14.4 RECENT DEVELOPMENTS 230
13.15 NIPR0 231
13.15.1 COMPANY SNAPSHOT 231
13.15.2 REVENUE ANALYSIS 231
13.15.3 PRODUCT PORTFOLIO 232
13.15.4 RECENT DEVELOPMENT 232
13.16 PFIZER INC 233
13.16.1 COMPANY SNAPSHOT 233
13.16.2 REVENUE ANALYSIS 233
13.16.3 PRODUCT PORTFOLIO 234
13.16.4 RECENT DEVELOPMENT 234
13.17 RECIPHARM AB. 235
13.17.1 COMPANY SNAPSHOT 235
13.17.2 REVENUE ANALYSIS 235
13.17.3 PRODUCT PORTFOLIO 236
13.17.4 RECENT DEVELOPMENT 236
13.18 SIEGFRIED HOLDING AG 237
13.18.1 COMPANY SNAPSHOT 237
13.18.2 REVENUE ANALYSIS 237
13.18.3 PRODUCT PORTFOLIO 238
13.18.4 RECENT DEVELOPMENTS 238
13.19 SUN PHARMACEUTICAL INDUSTRIES LTD 239
13.19.1 COMPANY SNAPSHOT 239
13.19.2 REVENUE ANALYSIS 239
13.19.3 PRODUCT PORTFOLIO 240
13.19.4 RECENT DEVELOPMENT 240
13.20 TE CONNECTIVITY 241
13.20.1 COMPANY SNAPSHOT 241
13.20.2 REVENUE ANALYSIS 241
13.20.3 PRODUCT PORTFOLIO 242
13.20.4 RECENT DEVELOPMENT 242
13.21 VETTER PHARMA-FERTIGUNG GMBH & CO. KG 243
13.21.1 COMPANY SNAPSHOT 243
13.21.2 PRODUCT PORTFOLIO 243
13.21.3 RECENT DEVELOPMENTS 243
14 QUESTIONNAIRE 244
15 RELATED REPORTS 247

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.